Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price19.98 USD
Fair value21.81
Ethical score70.0/100
Our investment reviews on this name
2026-09-14Read Markdown20.90-4.4% to today ✓
2026-08-14Read Markup20.29-1.5% to today
2026-07-02Read Accumulation17.08+17.0% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Stevanato Group S.p.A. holds its Markdown at $19.98. The statistical read favours the sellers, held for 39 days.
As held on the ledger · 2026-10-01
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 39 days
Price at the screen
$19.98
Valuation
35.68 trailing · 23.60 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.75
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
18.43%
Below 33%
Interest-bearing debt is just 18.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.05%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
17.03%
Below 49%
Money owed to the company is 17.0% of assets, under the 49% limit.
Pass
Revenue purity
0.09%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Stevanato Group S.p.A. clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 18%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-01 screen. The gold marker is the market price at the same screen. A 9.2% margin of safety to the base estimate.
Third-party analyst targets: 12 covering, consensus Buy. The average target sits +25% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Glass Vials Power Pharma Yet Returns Stay Modest
Every new drug or vaccine batch needs safe glass containers to reach patients, and Stevanato sits in that supply chain across Europe, the Americas and Asia. The business shows steady revenue growth of 7 percent, a 12 percent profit margin and 10 percent return on equity, with an ethical screen that clears our bar. Our fair value sits at 21.67 dollars against the current 19.17 dollar price, yet the opportunity rating stays at none because the margin of safety is thin and the forward multiple of 23 times leaves little room for error.
We pass because the numbers do not clear the threshold that would make this stand out from other medical supply names. Growth is single digit, returns on equity are average and no clear moat is visible, even though ten analysts carry a buy rating with a 25 dollar median target. A modest discount does not turn an ordinary healthcare supplier into a compelling case when better alternatives exist elsewhere.
Currency swings from euro exposure, dependence on big pharma spending cycles and competition from larger packaging groups all add real pressure. Without stronger growth or higher returns the valuation gap could close slowly or not at all.
The risks · The things to watch: its business and earnings are exposed to Italy and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
STVN trades on the NYSE (the company is based in Italy). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown$19.98-4.4%Entry 6
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (9 analysts) rates it buy, with a mean price target of $25. Insiders have been net sellers over the past quarter.
2026-09-14Markdown · changed$20.90+3.0%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (9 analysts) rates it buy, with a mean price target of $25.
2026-08-14Markup · changed$20.29+18.8%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 18.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (9 analysts) rates it buy, with a mean price target of $25.
2026-07-18Accumulation$17.08+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (9 analysts) rates it buy, with a mean price target of $25.
2026-07-03Accumulation$17.08+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$17.08Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
